Blood Res.  2021 Sep;56(3):205-207. 10.5045/br.2021.2020049.

Management of COVID-19-related immune thrombocytopenia by rhTPO

• Zhang X
• Li M
• Chen T
• Lv D
• Xia P
• Qian W

• KMID: 2520617
• DOI: http://doi.org/10.5045/br.2021.2020049

Abstract

No abstract available

Figure

• 

  Fig. 1 Dynamic profile of the complete blood count during hospitalization. Abbreviations: CBC, complete blood count; Hb, hemoglobin; IVIg, gamma globulin by intravenous infusion; Plt, platelet; rhTPO, recombinant human thrombopoietin.

Reference

1. Lambert MP, Gernsheimer TB. 2017; Clinical updates in adult immune thrombocytopenia. Blood. 129:2829–35. DOI: 10.1182/blood-2017-03-754119. PMID: 28416506. PMCID: PMC5813736.

2. Kistangari G, McCrae KR. 2013; Immune thrombocytopenia. Hematol Oncol Clin North Am. 27:495–520. DOI: 10.1016/j.hoc.2013.03.001. PMID: 23714309. PMCID: PMC3672858.

3. Magdi M, Rahil A. 2019; Severe immune thrombocytopenia complicated by intracerebral haemorrhage associated with coronavirus infection: a case report and literature review. Eur J Case Rep Intern Med. 6:001155. DOI: 10.12890/2019_001155. PMID: 31410357. PMCID: PMC6663043.

4. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. 2020; A novel coronavirus emerging in China - key questions for impact assessment. N Engl J Med. 382:692–4. DOI: 10.1056/NEJMp2000929. PMID: 31978293.

5. Lippi G, Plebani M. 2020; Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 58:1131–4. DOI: 10.1515/cclm-2020-0198. PMID: 32119647.

6. Zulfiqar AA, Lorenzo-Villalba N, Hassler P, Andrès E. 2020; Immune thrombocytopenic purpura in a patient with Covid-19. N Engl J Med. 382:e43. DOI: 10.1056/NEJMc2010472. PMID: 32294340. PMCID: PMC7179995.

7. World Health Organization. 2020. Clinical management of severe acute respiratory infection when novel coronavirus (nCov) infection is suspected. World Health Organization;Geneva, Switzerland: at https://www.who.int/publications/i/item/10665-332299. Accessed February 9, 2020. DOI: 10.15557/PiMR.2020.0003.

8. Zhao JP, Hu Y, Du RH, et al. 2020; Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 43:E007. DOI: 10.3760/cma.j.issn.1001-0939.2020.03.008. PMID: 32164084.

9. Purohit A, Aggarwal M, Singh PK, et al. 2016; Re-evaluation of need for bone marrow examination in patients with isolated thrombocytopenia contributors. Indian J Hematol Blood Transfus. 32:193–6. DOI: 10.1007/s12288-015-0533-2. PMID: 27065582. PMCID: PMC4788996.

10. Stasi R. 2012; Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost. 38:454–62. DOI: 10.1055/s-0032-1305780. PMID: 22753097.

11. Yang M, Ng MH, Li CK. 2005; Thrombocytopenia in patients with severe acute respiratory syndrome (review). Hematology. 10:101–5. DOI: 10.1080/10245330400026170. PMID: 16019455.

12. Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. 2019; Thrombopoietin receptor agonists: ten years later. Haematologica. 104:1112–23. DOI: 10.3324/haematol.2018.212845. PMID: 31073079. PMCID: PMC6545830.

13. Wang S, Yang R, Zou P, et al. 2012; A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol. 96:222–8. DOI: 10.1007/s12185-012-1124-8. PMID: 22753022.

14. Zhou H, Xu M, Qin P, et al. 2015; A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 125:1541–7. DOI: 10.1182/blood-2014-06-581868. PMID: 25575541. PMCID: PMC4351949.